PET shows effectiveness of gantenerumab for Alzheimer's disease

10/10/2011 | AuntMinnie.com (free registration)

PET with carbon-11-labeled Pittsburgh Compound B showed that treatment with an antibody called gantenerumab can reduce the levels of amyloid-beta plaque in the brains of patients with Alzheimer's disease, according to a Swiss study published in the Archives of Neurology. The reduction in the plaque was directly related to the size of the treatment dose, the researchers said. "Additionally, our findings in the placebo-treated patients support previous reports indicating that amyloid load continues to increase in many patients with mild-to-moderate Alzheimer's disease," the researchers added.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL